www.klinickafarmakologie.cz / Klin Farmakol Farm. 2025;39(2):89-95 / KLINICKÁ FARMAKOLOGIE A FARMACIE 95 HLAVNÍ TÉMA Primum non nocere: Jak bezpečná je moderní terapie roztroušené sklerózy? 26. Oksbjerg NR, Nielsen SD, Blinkenberg M, et al. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord. 2021;52. 27. Coles AJ, Jones JL, Vermersch P, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal. 2022;28(5):842-846. 28. Kim T, Brinker A, Croteau D, et al. Immune-mediated colitis associated with ocrelizumab: A new safety risk. Multiple Sclerosis Journal. 2023;29(10):1275-1281. 29. Maunula A, Atula S, Laakso SM, et al. Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective study. Mult Scler Relat Disord. 2024;81:105-134. 30. Lee JD, Chen T. Natalizumab Rebound in Multiple Sclerosis. Neurohospitalist. 2021;12(1):197. 31. Goh LY, Kirthi V, Silber E, et al. Real-world incidence of fingolimod-associated macular oedema. Mult Scler Relat Disord. 2020;42:102-125. 32. Kappos L, Fox RJ, Burcklen M, et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021;78(5):558-567. 33. Pierret C, Mulliez A, Le Bihan-Benjamin C, et al. Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study. Neurology. 2024;103(9):e209885. 34. Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: Findings from British Columbia, Canada. Brain. 2012;135(10):2973-2979. 35. Nørgaard M, Veres K, Sellebjerg FT, et al. Incidence of malignancy in multiple sclerosis: A cohort study in the Danish Multiple Sclerosis Registry. Mult Scler J Exp Transl Clin. 2021;7(4). 36. Liu Z, Fan T, Mo X, Kan J, Zhang B. Association between multiple sclerosis and cancer risk: A two-sample Mendelian randomization study. PLoS One. 2024;19:e. 37. Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler. 2015;21(3):263. 38. Grytten N, Myhr KM, Celius EG, et al. Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Multiple Sclerosis Journal. 2020;26(12):1569-1580. 39. Jiang M, Lam L, Zhuang YZ, et al. Incidence and Characteristics of Melanoma in Multiple Sclerosis Patients Treated With Fingolimod: A Systematic Review. Curr Dermatol Rep. 2023;12(4):300-313. 40. Riederer F. Ocrelizumab versus placebo in primary progressive multiple sclerosis. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2017;18(1):30-31. 41. Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: A population-based register study. Int J Cancer. 2006;118(4):979-984. 42. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. The Lancet. 201;378(9805):1779-1787. 43. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine. 2017;376(3):221-234. 44. Hauser SL, Kappos L, Arnold DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95(13):E1854-1867. 45. Kappos L, Traboulsee A, Li DKB, et al. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2024;271(2):642-657. 46. D’Amico E, Chisari CG, Arena S, et al. Cancer risk and multiple sclerosis: Evidence from a large Italian cohort. Front Neurol. 2019;10(APR). 47. Ryerson LZ, Foley J, Kister I, et al. Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) with Natalizumab Extended Interval Dosing (EID) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (P10-6.005). Neurology. 2024;102(17_supplement_1). 48. Štourač P, Bednářová J, Pavelek Z. Etiopathogenesis and diagnostics of progressive multifocal leukoencephalopathy in patients treated with natalizumab. Ceska a Slovenska Neurologie a Neurochirurgie. 2021;84(2):135-138. 49. Bou Rjeily N, Fitzgerald KC, Mowry EM. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity. Multiple Sclerosis Journal. 2024;30(2):257-260. 50. Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, et al. Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses. Front Neurol. 2021;12:416-548. 51. Tran TDQ, Hall L, Heal C, et al. Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study. BMJ Neurol Open. 2024;6(1):672. 52. Shirah BH, Algahtani H. Personalized Half-Dose Ocrelizumab in Selected Patients with Relapsing-Remitting Multiple Sclerosis. Mult Scler Relat Disord. 2023;71:104349. 53. Scavone C, Anatriello A, Baccari I, et al. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system. Frontiers in Neurology. 2024;15:1383910. 54. Newsome SD, Krzystanek E, Selmaj KW, et al. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. Neurology. 2025;104(9):e213574. 55. Theil D, Smith P, Huck C, et al. Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys. Front Immunol. 2019;10(JUN):453167. 56. Szepanowski F, Warnke C, Meyer zu Hörste G, et al. Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. CNS Drugs. 2021;35(11):1173-1188. 57. European Medicines Agency. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). 2021. Available from: https://www. ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin- -intravenous-administration-ivig-rev-4_en.pdf. 58. Buljevac D, Flach HZ, Hop WCJ, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(5):952-960. 59. Stastna D, Menkyova I, Drahota J, et al. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. Mult Scler Relat Disord. 2022;65:104014. 60. Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol [Internet]. 2017;264(6):10351050. 61. Horakova D. Doporučení Výboru Sekce klinické neuroimunologie a likvorologie ČNS ČLS JEP. 2021. Available from: www.aktivnizivot.cz. 62. Meltzer E, Campbell S, Ehrenfeld B, et al. Mitigating alemtuzumab-associated autoimmunity in MS: A ‘whack-a-mole’ B-cell depletion strategy. Neurology(R) neuroimmunology & neuroinflammation. 2020;7(6):e868. 63. Bierhansl L, Hartung HP, Aktas O, et al. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022;21(8):578. Available from: /pmc/articles/PMC9169033/. 64. Greenberg BM. Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier. Neurol Clin. 2024;42(1):155-163. 65. Study Details | Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis | ClinicalTrials.gov. Available from: https://clinicaltrials.gov/study/NCT06430671. 66. Rush CA, Atkins HL, Freedman MS. Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019;9(3):a029082. 67. Gupta S, Seshadri M, Lincoln R, et al. An Investigator Initiated Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis (S3.002). Blood. 2024;144(1):3469.1. 68. Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial – Tiziana Life Sciences [Internet]. Tiziana Life Science. Available from: https://www. tizianalifesciences.com/tiziana-life-sciences-announces- -johns-hopkins-university-commences-dosing-nasal-foralumab-in-phase-2-multiple-sclerosis-clinical-trial/?utm_ source=chatgpt.com. 69. Vermersch P, Granziera C, Mao-Draayer Y, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. New England Journal of Medicine. 2024;390(7):589-600. 70. ReMuS | Registr pacientů s roztroušenou sklerózou. Available from: https://www.multiplesclerosis.cz/.
RkJQdWJsaXNoZXIy NDA4Mjc=